Online pharmacies promoting GLP-1 treatments with phrases like "join the waitlist" and "pre-order" are facing repercussions from Britain's advertising regulator.
For the first time, the Advertising Standards Authority prohibited advertising for oral weight-loss medicines because they promoted unlicensed and prescription-only treatments directly to the public.
The rulings come at a sensitive moment for people seeking help with weight management, drawing a clear line between clinical care and consumer-style marketing for powerful prescription drugs.
Here's what to know
According to The Independent, the ASA ruled against Simple Online Pharmacy and Pharmacy Online, saying they had promoted oral GLP-1 medicines directly to consumers before the medications were authorized in the U.K.
A June 1 ad from Simple Online Pharmacy told people to "join the waitlist" for a new oral weight-management medicine. But as of June 1, no oral GLP-1 tablet for weight management had received U.K. prescription-only approval, which did not arrive until June 11, so the ad ran before marketing authorization was in place.
Before a medicine can be promoted in the U.K., the Medicines and Healthcare products Regulatory Agency must authorize it, and advertisers cannot make medicinal claims for treatments that have not been approved.
TCD Picks » Quince Spotlight
💡These best-sellers from Quince deliver affordable, sustainable luxury for all
The ASA also found Pharmacy Online's ads for the oral Wegovy tablet unlawful because they advertised prescription-only medicines to the public, which is illegal in the U.K. Those promotions included a website pop-up inviting people to "pre-order" the medicine and paid social media ads for an oral weight-management tablet.
The ASA issued three additional rulings against MedExpress, Juniper, and the Care Pharmacy, saying they had advertised prescription-only weight-loss medicines to the public without naming the products directly.
The watchdog said its research showed people could recognize an ad as referring to weight-loss medication even when no brand name appeared.
What's being done?
After banning the ads, the ASA told advertisers to consider how promotions look to ordinary people, not just whether they technically avoid naming a medicine.
The watchdog said it will continue monitoring advertising and related trends in coordination with the MHRA and the General Pharmaceutical Council.
The ASA said it issued a public health warning: "Advertising them irresponsibly or illegally can put people at risk, which is why this remains a priority for us."
Where can I learn more?
This case is part of a broader regulatory push to police how health-related products are marketed and sold.
• Coca-Cola now faces a false advertising lawsuit over allegedly misleading claims about soda ingredients.
• In Argentina, officials issued a strict reminder that the country's vape ban remains in force.
• In Denver, a referendum left a citywide vape ban hanging in the balance.
Get TCD's free newsletters for easy tips, smart advice, and a chance to earn $5,000 toward home upgrades. To see more stories like this one, change your Google preferences here.
